UNSPSC 51121500: Antiarrythmic agents

This classification denotes agents used for the treatment or prevention of disturbances of the normal rhythmic beating of the heart. they may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

UNSPSC 51121500 Antiarrhythmic agents is a Class code covering emergency and critical-care medications for cardiac stabilization that state and local governments procure for fire rescue services, hospital systems, and public health agencies. State and local buyers under this code source specific medications — epinephrine, adenosine, diltiazem, labetalol, and other cardiac drugs — in vial and injectable forms, with strict requirements for expiration dating, cold-chain handling, and rapid resupply. The issuing bodies span municipal fire rescue departments, state health and human services agencies operating pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating buys across state and local members. Recent activity shows fire departments and EMS services driving immediate, recurring demand through sealed-bid procurements, while state agencies and cooperatives are simultaneously exploring direct-to-manufacturer contracting models to optimize pricing and supply-chain efficiency for broader pharmacy programs.

The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent SLBE bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 with a response deadline of March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with pricing weighted at 75 percent and contract terms of two years from an effective date of July 1, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription contracting to supplement existing pharmacy benefit manager arrangements. Geographic activity concentrates in Florida, Texas, and the Upper Midwest, with municipal procurement representing the most immediate opportunity and state-agency cooperative vehicles representing longer-cycle, higher-volume purchasing channels.